In a patient with atrial fibrillation undergoing percutaneous coronary intervention, how should the timing of dual antiplatelet therapy (DAPT) and direct oral anticoagulants (DOACs) be managed?

Timing of DAPT and DOACs in Atrial Fibrillation Patients Undergoing PCI

For AF patients undergoing PCI, discontinue aspirin at or before hospital discharge in most cases, continue the DOAC (or restart within 24 hours post-PCI), and add clopidogrel as the sole antiplatelet agent for 6-12 months depending on presentation. 1

Immediate Post-PCI Management (First 24 Hours)

DOAC Timing

• Resume DOAC within 24 hours after PCI in most patients, potentially as early as the evening of the procedure day 1
• Timing depends on:
  • Access site hemostasis adequacy
  • Post-procedure bleeding complications
  • Body habitus (obese patients with femoral access need longer observation)
  • Coagulation abnormalities 1

Aspirin Management

• Give aspirin during hospitalization only (typically ≤81-100 mg daily) 1
• Stop aspirin at or before discharge in the majority of patients 1
• Exception: May continue aspirin up to 30 days only in patients with both high thrombotic risk AND low bleeding risk 1

Post-Discharge Antithrombotic Strategy

Default Dual Therapy Regimen

DOAC + Clopidogrel (without aspirin) is the standard approach 1

• Clopidogrel is strongly preferred over prasugrel or ticagrelor due to lower bleeding risk 1
• If patient was on prasugrel or ticagrelor pre-PCI, switch to clopidogrel 1

Duration Based on Presentation

For ACS patients:

• Continue clopidogrel + DOAC for 12 months 1
• After 12 months: DOAC alone lifelong 1

For stable ischemic heart disease (SIHD):

• Continue clopidogrel + DOAC for 6 months 1
• After 6 months: DOAC alone lifelong 1

DOAC Selection and Dosing

Preferred Approach

• Continue the same DOAC the patient was on pre-PCI 1
• If switching from warfarin, transition to a DOAC (preferred over continuing warfarin) 1

Special Dosing Considerations

Rivaroxaban (based on PIONEER-AF PCI trial):

• During combination therapy with antiplatelet: 15 mg daily (CrCl >50 mL/min) or 10 mg daily (CrCl 30-50 mL/min) 1
• After stopping antiplatelet: Increase to standard AF dose (20 mg daily or 15 mg if renally adjusted) 1

Other DOACs:

• Use standard FDA-approved AF doses during combination therapy 1

Triple Therapy: When and How Long

Avoid routine triple therapy (DOAC + aspirin + clopidogrel) 1

Rare Exceptions for Triple Therapy (up to 30 days maximum):

Only consider if ALL of the following apply:

• Very high thrombotic risk (complex PCI, left main stenting, last remaining vessel, stent thrombosis)
• Low bleeding risk
• ACS presentation 1

Duration: Shortest possible, typically ≤1 week, maximum 30 days 1, 2

Critical Pitfalls to Avoid

1. Do not continue aspirin long-term - Multiple trials (WOEST, PIONEER AF-PCI, RE-DUAL PCI, AUGUSTUS, ENTRUST-AF PCI) demonstrate dual therapy (DOAC + P2Y12 inhibitor) reduces bleeding without increasing ischemic events 1

2. Do not use prasugrel or ticagrelor with DOAC - Significantly increases bleeding risk without proven benefit 1, 3

3. Do not delay DOAC restart - Can typically resume within 24 hours unless significant bleeding concerns 1

4. Do not use warfarin when DOAC is feasible - DOACs have lower major, fatal, and intracranial bleeding rates 1

Warfarin-Specific Considerations (if DOAC contraindicated)

If patient must remain on warfarin:

• Continue aspirin 81 mg daily only until INR reaches 2.0-2.5 1
• Target INR 2.0-2.5 (lower end of therapeutic range) 1
• Consider bridging with parenteral anticoagulation only in high stroke risk patients 1

Evidence Strength

The recommendation for dual therapy over triple therapy is supported by five major randomized trials showing either non-inferiority or superiority for safety endpoints with no significant difference in ischemic outcomes 1. The 2020 ACC Expert Consensus provides the most comprehensive and recent algorithmic approach to this complex clinical scenario 1.